Stock Events

Stock Events

Lakefront Biotherapeutics NV 

€29.80
243
+€0.00+0%Friday 20:55

Statistics

Day High
30
Day Low
28.6
52W High
30.6
52W Low
22.2
Volume
-
Avg. Volume
-
Mkt Cap
1.96B
P/E Ratio
3.19
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 12Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-3.6
-2.3
-1
0.3
Expected EPS
-0.81291125708
Actual EPS
N/A

Financials

28.85%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.11BRevenue
320.88MNet Income

Analyst Ratings

$26.94Average Price Target
The highest estimate is ⁦34.15⁩.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GXEA.STU. It's not an investment recommendation.
ASML NV
22
ASML.AS
Shell
21
SHELL.AS
Prosus NV
18
PRX.AS
Alibaba Group
17
BABA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals is a direct competitor in the cystic fibrosis market, where both companies are developing treatments.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences collaborates with Galapagos on filgotinib but also competes in other areas of biopharmaceuticals, including antiviral drugs.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie competes in the immunology space, particularly in treatments for rheumatoid arthritis, where Galapagos also has interests.
AMGEN
AMGN
Mkt Cap251.94B
Amgen competes in the biotech space, focusing on innovative therapeutics, including areas like inflammation where Galapagos is active.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is involved in developing treatments for conditions like asthma and arthritis, directly competing with Galapagos' pipeline.
Biogen
BIIB
Mkt Cap37.49B
Biogen competes in the area of biopharmaceuticals with a focus on neurodegenerative diseases, an area Galapagos has shown interest in.
Novartis
NVS
Mkt Cap303.67B
Novartis competes across a broad range of therapeutic areas, including those targeted by Galapagos, such as autoimmune diseases.
Pfizer
PFE
Mkt Cap173.95B
Pfizer operates in various therapeutic areas, including inflammation and immunology, competing with Galapagos' research and development efforts.
Merck
MRK
Mkt Cap368.89B
Merck & Co. competes in the pharmaceutical and biotech sectors, focusing on innovative treatments that could overlap with Galapagos' interests.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca competes in multiple areas, including respiratory diseases, where Galapagos also focuses its research efforts.

About

Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
Show More
CEO
Henry Gosebruch
Employees
452
Country
Belgium
ISIN
US36315X1019
WKN
000A0YGNJ

Listings

BR
BE
LKFT.BR
AS
NL
LKFT.AS
SA
BR
LKFT34.SA
MU
DE
GXE.MU

0 Comments

Share your thoughts

FAQs

What is Lakefront Biotherapeutics NV stock price today?▼
The current price of GXEA.STU is €29.80 EUR — it has increased by +0% in the past 24 hours. Watch Lakefront Biotherapeutics NV stock price performance more closely on the chart.
What is Lakefront Biotherapeutics NV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Lakefront Biotherapeutics NV stocks are traded under the ticker GXEA.STU.
Is Lakefront Biotherapeutics NV stock price growing?▼
GXEA.STU stock has risen by +3.47% compared to the previous week, the month change is a +12.03% rise, over the last year Lakefront Biotherapeutics NV has showed a +8.76% increase.
What is Lakefront Biotherapeutics NV market cap?▼
Today Lakefront Biotherapeutics NV has the market capitalization of 1.96B
When is the next Lakefront Biotherapeutics NV earnings date?▼
Lakefront Biotherapeutics NV is going to release the next earnings report on November 12, 2026.
What were Lakefront Biotherapeutics NV earnings last quarter?▼
GXEA.STU earnings for the last quarter are 0.03 EUR per share, whereas the estimation was -0.69 EUR resulting in a +104.28% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Lakefront Biotherapeutics NV revenue for the last year?▼
Lakefront Biotherapeutics NV revenue for the last year amounts to 1.11B EUR.
What is Lakefront Biotherapeutics NV net income for the last year?▼
GXEA.STU net income for the last year is 320.88M EUR.
How many employees does Lakefront Biotherapeutics NV have?▼
As of November 7, 2026, the company has 452 employees.
In which sector is Lakefront Biotherapeutics NV located?▼
Lakefront Biotherapeutics NV operates in the Health & Wellness sector.
When did Lakefront Biotherapeutics NV complete a stock split?▼
Lakefront Biotherapeutics NV has not had any recent stock splits.
Where is Lakefront Biotherapeutics NV headquartered?▼
Lakefront Biotherapeutics NV is headquartered in Mechelen, Belgium.